Skip to main content

Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

·1 min

Merck (MRK) stock has seen a significant rise of more than 7% in the first week of 2024 due to growing excitement about its post-Keytruda prospects. Additionally, Merck announced the acquisition of Harpoon Therapeutics (HARP) for $680 million in the second week of 2024. Harpoon Therapeutics specializes in immuno-oncology, an area that aligns with Merck’s focus. Merck’s pipeline of late-stage tested drugs is projected to generate $13.6 billion in sales in 2029, following the expiration of Keytruda’s patent. Analysts believe that Merck’s diversified pipeline and strategic acquisitions will help the company navigate patent challenges and maintain growth.